Aurobindo Pharma shares rose 6.05 per cent to close the day at Rs 156.05, on completion of a licensing and supply agreement with Pfizer for supply of finished dosage products. Aurobindo has sold marketing rights for 39 generic solid oral dose products for the US and 20 for Europe.
These medicines cover the therapeutic areas, including cardiovascular disease and central nervous system disorders. The stock made an intraday high of Rs 163.45 and a low of Rs 144.05 with trading volumes of 1.67 lakh shares (around 4-times higher than its two-week average).
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app